Curasight A/S

Equities

CURAS

DK0061295797

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 18:00:00 2024-05-23 EDT			5-day change	1st Jan Change
9.54 ^DKK	-7.38%		-2.25%	-46.25%

05-23	Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	CI

BioStock: Curasight gears up for phase II study in prostate cancer

December 22, 2023 at 03:16 am

Following the Curium deal this spring, Curasight has now submitted a clinical trial application and selected a CRO to carry out a phase II trial with uTRACE. The trial intends to evaluate the uTRACE for the diagnosis of prostate cancer patients. BioStock contacted Curasight CEO Ulrich Krasilnikoff to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/12/curasight-gears-up-for-phase-ii-study-in-prostate-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/curasight/r/biostock--curasight-gears-up-for-phase-ii-study-in-prostate-cancer,c3897719

Latest news about Curasight A/S

Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	04-16	CI
Curasight A/S Announces Board Changes	04-12	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	02-13	CI
Curasight Gears Up for Phase II Study in Prostate Cancer	12-22	CI
Curasight A/S Submits Clinical Trial Application for Phase 2 Trial with Utrace	12-18	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-23	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer	23-10-18	CI
Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress 2023 in Prague	23-09-14	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer	23-06-29	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)	23-06-07	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Curasight Secures Global License Agreement for Utrace in Prostate Cancer	23-05-11	CI
Curasight A/S Enters into an Exclusive Global License and Collaboration Agreement with Curium Inc	23-05-01	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors	22-10-13	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer	22-06-30	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-24	CI

Chart Curasight A/S

Duration

Period

More charts

Company Profile

Curasight A/S is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). The technology provides improved diagnosis and risk stratification in multiple cancer types.

Sector

Biotechnology & Medical Research

Calendar

2024-06-07 - Society of Nuclear Medicine & Molecular Imaging Meeting

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURASIGHT A/S	-46.25%	29.72M
MODERNA, INC.	+67.53%	62.86B
IQVIA HOLDINGS INC.	-0.77%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.9B
BIO-TECHNE CORPORATION	+4.70%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.27B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research